Concourse Financial Group Securities, Inc. Erasca, Inc. Transaction History
Concourse Financial Group Securities, Inc.
- $0
- Q2 2025
Number of Shares
0
Previous 0
NaN%
Holding current value
$0
Previous $0
NaN%
% of portfolio
100.0%
Previous 100.0%
Shares
17 transactions
Others Institutions Holding ERAS
# of Institutions
153Shares Held
216MCall Options Held
258KPut Options Held
0-
Frazier Life Sciences Management, L.P. Menlo Park, CA22.7MShares$51.6 Million1.52% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD20.3MShares$46.2 Million0.02% of portfolio
-
Vr Adviser, LLC New York, NY17.9MShares$40.5 Million4.49% of portfolio
-
Logos Global Management LP San Francisco, CA15MShares$34.1 Million2.46% of portfolio
-
Suvretta Capital Management, LLC New York, NY14.5MShares$32.9 Million0.63% of portfolio
About Erasca, Inc.
- Ticker ERAS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 122,147,000
- Market Cap $277M
- Description
- Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; ...